Background: The X-ACT study aimed to examine the effect of omalizumab treat-
| INTRODUCTION
Chronic spontaneous urticaria (CSU) involves the repeated occurrence of wheals (hives), angioedema, or both for more than 6 weeks, without any specific external trigger. 1, 2 Angioedema is an important symptom associated with CSU; it is characterized by a sudden swelling of the dermis, subcutaneous tissue, mucosa, and/or submucosa, which usually occurs around the eyes, lips and mouth, arms and legs, genitalia, or hands. 3 Approximately 33%-67% of CSU patients reportedly experience wheals and angioedema, and 1%-13% reportedly experience only angioedema. 4 Furthermore, recent data from the observational AWARE study indicate that 46.1% of German CSU patients, who remained symptomatic despite treatment with at least the approved dose of H 1 -antihistamines, had both, wheals and angioedema, while 2.9% exclusively had angioedema. 5 Angioedema is a major driver of quality-of-life (QoL) impairment in patients with CSU. 6 Owing to the unpredictable development of disfigurement and/or functional impairment, angioedema episodes can have a significant impact on daily activities and social interactions in CSU patients. 4 Furthermore, patients report missing work or school owing to their angioedema.
Omalizumab is approved as an add-on therapy in patients with CSU refractory to H 1 -antihistamines. 7 Several randomized controlled trials (RCTs) have shown that omalizumab effectively controls the symptoms of CSU (itching and wheals) [8] [9] [10] [11] [12] [13] [14] and improves the QoL in CSU patients. [8] [9] [10] [11] [12] [13] [14] [15] [16] We recently reported that subcutaneous omalizumab (300 mg) also reduces the frequency and severity of angioedema in H 1 -antihistamine-refractory CSU patients. 4 Furthermore, omalizumab reduced QoL impairment in the same patient cohort, 4 as assessed using the validated CSU-specific QoL Questionnaire (CU-Q 2 oL). However, a number of questions remain unanswered for H 1 -antihistamine-refractory CSU patients with angioedema: (1) Are specific domains of QoL and psychological well-being more severely affected than other aspects at baseline?
(2) Do angioedema-related QoL scores and psychological well-being improve over the course of omalizumab treatment? and (3) Are improvements in symptom severity correlated with changes in QoL?
Here, we present results from the X-ACT (Xolair Effects on Angioedema in Chronic Spontaneous Urticaria Treatment) study, to bridge the gaps in the knowledge on angioedema-related QoL impairment and improvement with omalizumab treatment.
2 | ME TH ODS 2.1 | X-ACT study design X-ACT was a randomized, double-blind, placebo-controlled, multicenter, phase III study that has previously been described in detail. 4 The trial was conducted between January 2013 and May 2014 in 24 centers across Germany. Briefly, the study was divided into a 2-week screening period, a 28-week double-blind treatment phase in which patients were randomized (1:1) to receive subcutaneous injections of omalizumab 300 mg or placebo every 4 weeks from baseline (Week 0) until Week 24, and an 8-week follow-up phase ( Figure 1 
| Study patients
Male and female CSU patients aged 18-75 years with a history of angioedema (at least 4 episodes within the last 6 months before study enrollment), who remain symptomatic despite the use of twoto-four times the recommended dose of second-generation H 1 -antihistamine treatment, with an urticaria activity score (UAS) over 7 days (UAS7) of ≥14 and a CU-Q 2 oL score of ≥30 at baseline were included in the study. Patients underwent a clinical examination by an experienced physician, and a thorough history was taken; the presence of any form of chronic inducible urticaria was explicitly checked for, including delayed pressure urticaria which can be mistaken for angioedema. Patients were excluded from the study if they had non-urticaria-associated angioedema (eg, low C1-inhibitor levels), serious psychological disturbance, metabolic and pathological conditions, history of malignancy, hypersensitivity to omalizumab, or had received treatment with omalizumab within the previous 6 months.
| Study objectives and endpoints
The primary objective of the X-ACT trial was to evaluate the efficacy of once-monthly add-on injections of omalizumab (300 mg; subcutaneously for 28 weeks) compared to placebo on the QoL of CSU patients with angioedema refractory to H 1 -antihistamines (CU-Q 2 oL). 4 Key secondary endpoints included changes in angioedema disease activity, as well as angioedema-specific and overall skinrelated QoL impairment following omalizumab treatment.
2.4 | Patient-reported outcomes: disease activity, QoL, and psychological well-being
The Angioedema Activity Score (AAS) was completed by patients on a daily basis and recorded in a paper-based symptom diary. The AAS is a validated questionnaire that consists of an opening question (Have you had a swelling episode in the last 24 h?), followed by the five specific AAS questions to determine the severity and impact of the angioedema episode. 12 The daily AAS values are added over 
| RESULTS
A total of 91 CSU patients were randomized to one of two groups:
omalizumab (n = 44) or placebo (n = 47; Figure 1 ). On average, patients experienced 2.7 and 3.4 angioedema-burdened days during the screening phase (Week À2 to Week À1) in the omalizumab and placebo group, respectively. The mean (SD) AAS7 scores at baseline were also high in both the omalizumab (22.5 [20.6] ) and placebo (28.1 [24.1] ) groups indicating that angioedema activity was high (Table 1) . Baseline demographics and disease characteristics have been reported in detail previously. 4 The mean (SD) AE-QoL total scores (omalizumab 300 mg:
56.2 [18.7] ; placebo: 59.9 [19.2] ) were also high at baseline, reflecting poor QoL in these patients ( Table 1 ). The most severely affected subdomains of the AE-QoL were fears/shame, fatigue/mood, and functioning ( Table 2 ). The subdomain of food was less severely affected, but still indicated impairment in both groups. The mean DLQI total scores (omalizumab: 14.6 [5.7] ; placebo: 16.6 [7.3] ) also reflected poor QoL. The most severely affected subdomains of the DLQI score were symptoms and feelings, daily activities, and leisure. Total and subdomain scores were comparable for the omalizumab and placebo groups at baseline (Tables 1 and 2 ). 
Were you afraid of a life-threatening swelling episode? Never The AE-QoL and DLQI scores decreased rapidly following initiation of omalizumab treatment, and the improvements increased further throughout the treatment period (Figure 2A and B (P = .500); and treatment, À0.6 vs. À0.8 (P = .412) ( Table 2 ).
| Fear of life-threatening angioedema is reduced during omalizumab treatment
At baseline, when we asked patients whether they were afraid of a life-threatening swelling episode, 66.7% responded "occasionally," "often," or "very often." Similarly, 48.9% of patients were "occasionally" to "very often" afraid that "they could suffocate due to a swelling episode," emphasizing the gravity of the burden of disease these patients experience (Table 2 ).
After 28 weeks of omalizumab treatment, only a minority of patients still experienced these fears: 13.6% were "occasionally" to "very often" afraid of life-threatening swelling compared to 41.7% in the placebo group, and 4.5% were "occasionally" to "very often"
F I G U R E 2 LS mean changes in (A) AE-QoL total scores (observed values), (B) DLQI scores (LOCF)
, and (C) weekly AAS scores (zero was imputed for missing AAS day sum scores) from baseline. The values represented are the LS mean change from baseline for the FAS, using analysis of covariance. *indicates P < .05, **indicates P < .01, and ***indicates P < .001 (LS mean for difference between treatment groups; ANCOVA model). 
| General psychological well-being improves with omalizumab treatment
At baseline, the WHO-5 score indicated a signal for depression in both groups (mean score below the depression threshold of 13; Table 1 
| Improvement in angioedema symptoms is correlated with health-related QoL
Angioedema-related QoL improved with improved AAS scores.
Changes in total AE-QoL and AAS7 scores from baseline were significantly correlated at Week 12 (0.526, P < .001) and at Week 28 (0.501, P < .001). Furthermore, changes in weekly AAS scores correlated with changes in DLQI and WHO-5 scores at Week 12 (0.518, P < .001 and À0.319, P = .007, respectively) and Week 28 (0.546, P < .001 and À.321, P = .009, respectively).
Subgroup analyses revealed that female patients had higher AEQoL scores at baseline compared to male patients (P = .001; (Table 3 ).
| DISCUSSION
To our knowledge, X-ACT is the first study designed to investigate the effects of omalizumab 300 mg treatment on the impact of angioedema on QoL in patients with moderate-to-severe CSU. Our findings show that antihistamine-refractory CSU patients with angioedema experience significant QoL impairment, general psychological impairment, and fear of life-threatening angioedema episodes at baseline, all of which rapidly reduced following the initiation of omalizumab treatment.
We have previously reported that omalizumab treatment significantly reduced the disease activity (AAS7), improved CSU-related QoL, and reduced number of angioedema-burdened days per week and size of individual swelling episodes. 4 We also observed a rapid improvement in angioedema-related QoL and psychological wellbeing as well as reduced angioedema-related fears, which continued to improve over the course of omalizumab treatment. The rapid improvements in symptoms and QoL observed in these CSU patients are consistent with previous CSU trials, where omalizumab led to a rapid decrease in CSU symptoms and QoL impairment. 12, 13, 21 In addition, a recent analysis of three phase 3 studies showed that omalizumab 300 mg significantly improved total DLQI scores vs. placebo, with a mean decrease from baseline to Week 12 of À10.3 vs.
À6.1 (P < .0001) in ASTERIA I, À10.2 vs. À6.1 (P = .0004) in ASTERIA II and À9.7 vs. À5.1 (P < .0001) in GLACIAL. 22 The proportion of patients in whom changes in mean total DLQI score from baseline to Week 12 reached a minimal clinically important difference (MCID) of ≥4 was 74.1%, 76.0%, and 77.2% in ASTERIA I, II, and GLACIAL, respectively (P < .01; all studies). 22 Clinical observations indicate that the onset of omalizumab effect may be even earlier than 4 weeks, but data from controlled clinical trials are missing.
Improvements in the AE-QoL total scores in this study indicate a clinically meaningful benefit with omalizumab treatment; mean improvements were approximately 6.5 times higher than the | 581 previously reported MCID of the total AE-QoL score (6 points) 18 and correlated well with improved AAS7 scores. Moreover, the change in DLQI score was also above the previously defined MCID threshold of 2.2 to 3.1 points. 23 Interestingly, these rapid QoL improvements were not only visible in the total score but also in all but one of the AE-QoL subdomain scores. The rapid decreases in the AE-QoL subdomain scores indicate that patient's QoL is restored, their functioning in daily life and work life returns to a normal level, they overcome their sleeping problems and depressive mood, as well as their fears and embarrassment associated with the swellings. This observation surpassed our expectations, as it was thought that some subdomains, such as fear/shame, could have been less responsive to omalizumab treatment, or could have responded more slowly. The rapid reduction in QoL appears to be directly associated with the rapid reduction in the frequency and severity of angioedema. In line with this and as reported previously, symptoms began to reappear, and QoL scores worsened again to placebo levels following omalizumab discontinuation. 4, [11] [12] [13] Angioedema can be mediated by histamine or bradykinin. Hereditary angioedema (HAE) 12 is bradykinin-mediated and usually develops over the course of several hours, whereas in CSU, angioedema is histamine-mediated and develops rapidly. 24 For HAE patients, angioedema episodes can range from a minor inconvenience to lifethreatening episodes, with a mortality rate of approximately 30% in the case of laryngeal edema. 25 In contrast, angioedema is not considered life-threatening for CSU patients. Despite this, the majority of patients Chronic spontaneous urticaria patients are reported to have an increased risk of psychiatric comorbidities, including depression. [27] [28] [29] In patients with other chronic diseases, depression has been associated with decreased treatment adherence, sleep disturbance, and negative perception of the illness. 30 Here, the mean WHO-5 score was <13 for both treatment groups at baseline, indicating that depression may be present in these patients and that CSU with angioedema must not be classified as a trivial disease or just a cos- These results suggest that the psychological symptoms observed in CSU patients may be a reaction to the dermatological symptoms experienced; however, further research is required to confirm this.
| Limitations
This study only considered CSU patients with wheals and angioedema, although there are CSU patients with angioedema without/ with almost no wheals, who require adequate therapy. Based on the rapid improvement in angioedema activity and angioedema-related QoL observed in the X-ACT patient population, CSU patients without wheals would also likely benefit from omalizumab treatment;
however, further studies are warranted in this specific patient population. Furthermore, only adult patients were enrolled in the X-ACT study; therefore, it is unclear whether these results can be extrapolated to children and adolescents with CSU. Finally, the use of concomitant psychological medications was permitted in the X-ACT study and their use may be regarded as a surrogate for the presence of mild psychiatric/psychological comorbidities that may negatively impact QoL and psychological well-being. However, their use was low and was comparable between the omalizumab (n = 4) and placebo (n = 5) groups. Thus, the expected impact on the outcome parameters is low.
| CONCLUSIONS
Patients with moderate-to-severe CSU with angioedema that is refractory to high doses of H 1 -antihistamines have impaired QoL, fear of suffocation due to swelling episodes, and impaired psychological well-being, including an increased risk for signs of depression.
This study revealed that omalizumab is a highly effective treatment for this patient cohort and is associated with a marked and rapid improvement in angioedema symptoms, angioedema-related QoL, symptom-related fears, and psychological well-being. Based on these findings, we recommend that omalizumab is prescribed for the treatment of patients with severe H1-antihistamine-refractory CSU with angioedema.
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